南昌看焦虑症去哪家医院效果最好南昌市哪家发狂医院好,南昌神经病专治中心,南昌市第十二医院排名,南昌抑郁哪里医院看,南昌市第十二医院看精神科专业嘛收费贵吗,南昌哪家治疗精神障医院好,南昌治疗抑郁中医院

BANJUL, June 24 (Xinhua) -- Deputies at the Gambian National Assembly (parliament) on Friday passed a new bill entitled the "Food Safety and Quality Bill 2011".Under the new act, food operators are obliged to ensure food safety, quality production, processing and distribution within the business under their control and that their products must satisfy the requirements and regulations as demanded.Submitting the motion before deputies, Vice President and Minister for Women Affairs Isatou Njie-Saidy warned that the well- being of "our citizenry is at stake.""Giving our continuous drive to place health care on top of our development agenda, we call on all and sundry to join the bandwagon in the implementation of this bill," she said.She told deputies that the bill and the establishment of the Gambia Food Safety and Quality Authority is consistent with the regulation worked out by the West African bloc ECOWAS on the health and safety of plants, animals and food in the region.The Gambia Food Safety and Quality Authority being established by this bill will be the sole national competent authority having unitary responsibility for food safety and quality, she declared."In order to achieve the general objectives of a high level of protection of human health and life, measures applied under this Act shall be based on risk assessment," she added.

BEIJING, Sept. 6 (Xinhuanet) -- The amount of space junks floating in Earth's orbit has reached a critical level, warned scientists.The future space missions may become too dangerous to fly for a risk of colliding with space junks, said a report released recently by the U.S. National Research Council (NRC).The kinds of space junks range from huge, the report said, there are thousands of discarded satellites and rocket boosters and countless tiny pieces of daily gabages from space missions.The debris are traveling in orbit at 17,500mph, at such a speed even a tiny clash can destroy a spacecraft.The NRC recommended that NASA should launch a plan to clean up the floating debris and called on other major space nations' cooperation."The current space environment is growing increasingly hazardous to spacecraft and astronauts," said Kessler, an ex-NASA researcher, "NASA needs to determine the best path forward for tackling the multifaceted problems caused by meteoroids and orbital debris that put human and robotic space operations at risk."

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, July 11 (Xinhuanet) -- U.S. federal government officially announced that it denied the medical use of marijuana."Department of Health and Human Services concluded that marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision," U.S. Department of Justice declared Friday.The announcement will keep marijuana in the classification of dangerous, addictive drug as heroin.The decision comes almost nine years after medical marijuana advocates asked the government to reclassify marijuana, as its therapeutic effectiveness in treating some diseases and relieving pain of patients.Joe Elford, the chief counsel for Americans for Safe Access (ASA), said he was not surprised by the government's disapproval."It is clearly motivated by a political decision that is anti-marijuana," He noted.This is the third petition to reclassify marijuana has failed to be approved. The former two were filed in 1972 and in 1995, respectively.

BEIJING, July 19 (Xinhuanet) -- Lifestyle changes such as exercise, eating healthily and not smoking could reduce the chances of having Alzheimer’s disease by half, researchers said in a study quoted by news reports Tuesday.Hundreds of thousands of patients could potentially avoid the devastating illness by simply changing bad habits, according to the study published in the journal Lancet NeurologyFor the first time, scientists have calculated the extent to which certain lifestyle traits -- including lack of exercise, smoking and obesity -- all contributed to the disease.Researchers found that in the Western world, an inactive “couch potato” lifestyle was the most important possible cause.Smoking, obesity in middle-age, high blood pressure and diabetes all increased the risk as they cause damage to blood vessels in the brain, leading to death of brain cells. Together, the modifiable risk factors contributed to 50 percent of Alzheimer’s cases worldwide.The researchers want to carry out more work to find out how many people can prevent the disease by making small changes to their lifestyle.